In vitro and in vivo antitumor activities of oHSV-BJ-2 oncolytic virus

Abstract

Objective: To construct an oncolytic herpes simplex virus oHSV-BJ-2 and to evaluate its safety and antitumor efficacy. Methods: Using the HSV-1 wild-type KOS strain as the backbone, we constructed an oncolytic herpes simplex virus, oHSV-BJ-2. The CCK-8 method was used to detect the killing effect of the virus on eight tumor cell lines, and the in vivo tumor inhibitory effect of the virus was evaluated in the BALB/c nude mouse subcutaneous transplant tumor model (PANC-1, SW1990). Results: oHSV-BJ-2 showed a significant killing effect on seven tumor cell lines in a time- and dose-dependent manner. In the PANC-1 and SW1990 pancreatic cancer xenograft tumor models, intratumoral injection of oHSV-BJ-2 could significantly inhibit tumor growth, with the tumor inhibition rate reaching 70%-80% in the medium and high-dose groups, without a significant impact on the body weight of the mice. Conclusions: oHSV-BJ-2 has good safety and significant antitumor activity, and could be explored as a new drug candidate for the treatment of pancreatic cancer and other malignant tumors.

Keywords

Oncolytic virus / HSV-1 / ICP27 / Viral therapy / Tumor specific promoter / In vitro / In vivo / oHSV-BJ-2 / KOS / Mice

References

[1] Davodabadi F, Sajjadi SF, Sarhadi M, Bastami M, Mirghaderi SP, Sarhadi M, et al. Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery. Eur J Pharmacol 2023; 957: 176013. doi: 10.1016/j.ejphar.2023.176013.

[2] Duan C, Yu M, Xu J, Li BY, Zhao RJ, Kankala RK, et al. Overcoming cancer multi-drug resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed Pharmacother 2023; 162: 114643. doi: 10.1016/j.biopha.2023.114643.

[3] Chen X, Yu S, Tang Y, Guo Y, Li S, Cao J, et al. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer 2023; 22: 96. doi: 10.1186/s12943-023-01801-2.

[4] Lin D, Shen Y, Liang T. Oncolytic virotherapy: Basic principles, recent advances and future directions. Signal Transduct Target Ther 2023; 8(1): 156. doi: 10.1038/s41392-023-01407-6.

[5] Yu Z, Sathyanarayana P, Liu C, Tan JMJ, Yang P, Das B, et al. Mechanisms of HSV-1 helicase-primase inhibition and replication fork complex assembly. Cell 2026; 189(2): 478-494.e18.

[6] Esteves M, Matos AM, Cruz MT. Oncolytic viruses: A novel therapeutic approach for pancreatic cancer. Mol Ther Oncol 2025; 33(4): 201069. doi: 10.1016/j.omton.2025.201069.

[7] Zhou M, Shen Z. Advanced progress in the genetic modification of the oncolytic HSV-1 virus. Front Oncol 2025; 14: 1525940. doi: 10.3389/fonc.2024.1525940.

[8] Chouljenko DV, Murad YM, Lee IF, Walker JD, Kousoulas KG, Blum JS, et al. Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1. Mol Ther Oncolytics 2023; 28: 334-348. doi: 10.1016/j.omto.2023.02.003.

[9] Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: A phase 2 trial. Nat Med 2022; 28(8): 1630-1639.

[10] Toropko M, Chuvpilo S, Karabelsky A. miRNA-mediated mechanisms in the generation of effective and safe oncolytic viruses. Pharmaceutics 2024; 16(8): 986. doi: 10.3390/pharmaceutics16080986.

[11] Glorioso JC, Cohen JB, Goins WF, Hall B, Jackson JD, Grandi P, et al. Oncolytic HSV vectors and anti-tumor immunity. Curr Issues Mol Biol 2021; 41: 381-468.

[12] Birkenheuer CH, Baines JD. Aberrant RNA polymerase initiation and processivity on the genome of a herpes simplex virus 1 mutant lacking ICP27. J Virol 2024; 98(6): e00712-24. doi: 10.1128/jvi.00712-24.

[13] Sanders LS, Comar CE, Srinivas KP, Diggins NL, Gray R, Ibarra AJ, et al. Herpes simplex virus-1 ICP27 nuclear export signal mutants exhibit cell type-dependent deficits in replication and ICP4 expression. J Virol 2023; 97(7): e01957-22. doi: 10.1128/jvi.01957-22.

[14] Robilotti E, Zeitouni NC, Orloff M. Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy. Front Mol Biosci 2023; 10: 1178382. doi: 10.3389/fmolb.2023.1178382.

[15] Epstein AL, Rabkin SD. Safety of non-replicative and oncolytic replication-selective HSV vectors. Trends Mol Med 2024; 30(8): 781-794. doi: 10.1016/j.molmed.2024.05.014.

[16] Feng Y, Yang H, Liang G, Chen J, Li T, Wang Y, et al. Immune checkpoint inhibitors combined with oncolytic virotherapy: Synergy, heterogeneity, and safety in cancer treatment. Oncol Res 2025; 33(12): 3801-3836. doi: 10.32604/or.2025.067824.